Prevention and Treatment of Bleeding by Pro-hemostatic Treatment Strategies

Wiener Medizinische Wochenschrift

Volumn 153, Issue 19-20, 2003, Pages 421-425

  Levi, Marcel ^a,b   Vink, Roel ^a   De Jonge, Evert ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Activated factor VII; Antifibrinolytic therapy; Bleeding; Desmopressin; Hemostasis; Plasma transfusion

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; FIBRIN; HEMOSTATIC AGENT; LYSINE DERIVATIVE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ANAPHYLAXIS; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; META ANALYSIS; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOSIS;

ANTIFIBRINOLYTIC AGENTS; BLOOD TRANSFUSION; COAGULANTS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIIA; HEMOSTASIS, SURGICAL; HUMANS; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

EID: 0242361064     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-003-0029-9     Document Type: Review

References (29)

1. Carless PA, Anthony DM, Henry DA: Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg 2002;89:695-703.
2. de Jonge E, Levi M: Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001; 29:1261-1267.
3. Edmunds LH, Salzman EW: Hemostatic problems, transfusion therapy, and cardiopulmonary bypass in surgical patients. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice. J.W. Lippincott, Philadelphia, 1994.
4. Francis JL: The use of drugs to reduce blood loss during surgery. Hematol Rev 1992;7:85-99.
5. Fremes SE, Wong BI, Lee E, Mai R, Christakis GT, McLean RF, Goldman, BS, Naylor CD: Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-1588.
6. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-205.
7. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR: Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001;103:2555-2559.
8. Hedner U: NovoSeven® as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000;11:107-111.
9. Hellstern P, Muntean W, Schramm W, Seifried E, Solheim B: Practical guidelines for the clinical use of plasma. Thromb Res 2002;107 [Suppl 1]:S53.
10. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71:402-405.
11. Hoffman M, Monroe DM, Roberts HR: Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9 [Suppl 1]:S61-S65.
12. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E: Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002;123:118-126.
13. Levi M, Cromheecke ME, de Jonge E, Prins MH, del Mol BJ, Briet E, Buller HR: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-1947.
14. Levi M, van der Poll T: Hemostasis and coagulation. In: Norton J, Chang AE, Lowry SF (eds) Surgery: scientific basis and current practice. Springer, New York 2001.
15. Levi M, Vink R: Prohemostatic therapy for prevention and treatment of bleeding. Yearbook of Intensive Care and Emergency Medicine 2002;649-660.
16. Levi M, Vink R, de Jonge E: Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002;76 [Suppl 2]:139-144.
17. Lim RC, Olcott C, Robinson AJ: Platelet response and coagulation changes following massive blood replacement. J Trauma 1973;18:577-581.
18. Limentani SA, Roth DA, Furie BC, Furie B: Recombinant blood clotting proteins for hemophilia therapy. Semin Thromb Hemost 1993;19:62-72.
19. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-2521.
20. Mannucci PM: Hemostatic drugs. N Engl J Med 1998;339:245-253.
21. Mannucci PM, Remuzzi G, Pusinri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS: De-amino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
22. Mannucci PM, Tuddenbam EG: The hemophilias: progress and problems. Semin Hematol 1999;36:104-117.
23. McLeod BC: Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990;336:1137-1138.
24. Porte RJ, Leebeek FW: Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002;62:2193-2211.
25. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT: Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355:1303-1309.
26. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni, Barbui T, Mandelli F, Sirchia G: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997;337:1870-1875.
27. Richardson DW, Robinson AG: Desmopressin. Ann Intern Med 1985;103:228-239.
28. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K: The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 2002;53:252-257.
29. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-796.